Trial · NCT01115790
A Phase 1 Study in Participants With Advanced Cancer
NCT01115790, Phase 1, Completed, Eli Lilly and Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 1 Study in Participants With Advanced Cancer. Trials, record NCT01115790. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01115790
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 1 Study in Participants With Advanced Cancer
- NCT number
- NCT01115790
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 150 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV, Anal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
- Interventions
- Prexasertib
- First posted
- 2010-05-04
- Last updated
- 2016-05-10
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determination of a Recommended Phase 2 Dosing Regimen: Maximum Tolerated Dose (Parts A and B) | Time of first dose until last dose (estimated as up to 156 weeks) | |
| Primary | Determination of Clinically Significant Safety Effects (Parts A and B) | Time of first dose until last dose (estimated as up to 156 weeks) | |
| Primary | Percentage of Participants With a Complete or Partial Response (Overall Response Rate) (Part C) | Baseline until disease progression or death from any cause (estimated as up to 24 weeks) | |
| Secondary | Percentage of Participants with Complete Response, Partial Response, or Stable Disease (Disease Control Rate) (Parts A, B, and C) | Baseline until disease progression or death from any cause (estimated as up to 24 weeks) | |
| Secondary | Progression Free Survival (Parts B and C) | Baseline to measured progressive disease (estimated up to 24 weeks) | |
| Secondary | Duration of Response (Parts B and C) | First observation of complete response (CR), partial response (PR), or stable disease (SD) to first observation of progressive disease or death (estimated up to 24 weeks) | |
| Secondary | Preliminary Pharmacokinetics of Prexasertib (Cmax) (Parts A, B, and C) | During Cycles 1 and 2 | |
| Secondary | Preliminary Pharmacokinetics of Prexasertib (AUC) (Parts A, B, and C) | During Cycles 1 and 2 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01115790
GET https://conductscience.org/api/trials/v1/NCT01115790/registered